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Abstract
Background: It is unknown to what extent General Practitioners (GPs) manage hypertension (HT) differently in
older patients, as compared to younger age groups. The purpose of our study was to compare HT management in
older patients to younger age groups.
Methods: We performed a retrospective cohort study of patients of 159 GP's practices in the Integrated Primary
Care Information (IPCI) database. The study period lasted from September 2010 through December 2012.
The study population consisted of all patients aged 60 years or older with at least one blood pressure (BP)
measurement during the inclusion period, without pre-existent HT, diabetes mellitus (DM) or atherosclerotic
cardiovascular disease at time of study start.
Study outcomes were a diagnosis of HT within one month after cohort entry and the use of antihypertensive
medication within 4 months after cohort entry in HT diagnosed patients.
We compared the incidence of outcomes between the age groups, stratified by systolic blood pressure (SBP).
Logistic regression analysis was used to assess the influence of age-adjusted SBP Z-scores, age and gender on the
outcomes.
Results: We included 19,500 patients from 159 GP’s practices of whom 1,181 (6.1 %) were newly diagnosed with
HT. Corrected for age-adjusted SBP, older patients were less likely to be diagnosed with HT (odds ratio per year age
increase 0.98, p < 0.001). Corrected for age-adjusted SBP, no significant effect of age on the probability of treatment
in newly diagnosed HT patients was observed (p = 0.82).
Conclusions: This study showed that GPs are less inclined to diagnose HT with increasing patient age, but do not
withhold treatment when they diagnose HT in older patients.
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Background
Evidence on the effectiveness of treatment of hyperten-
sion (HT) in patients of 80 years and older is conflicting
[1–4]. Traditionally older patients were ignored in Dutch
guidelines as patients up to 65 years old were treated ac-
cording to their risk estimate of atherosclerotic cardio-
vascular disease, for which blood pressure (BP) was one
of the criteria [5]. For older patients however, the gen-
eral practitioner (GP) had to rely on his/her clinical
judgment, which varied widely as to when it was appro-
priate to start treatment [6].
In 2008 the Hypertension in the Very Elderly Trial
(HYVET) [1] indicated that treatment of HT in patients
of 80 years and older was beneficial on mortality from
stroke and overall mortality. There is evidence that high
BP is not associated with a higher risk of death in the
frail [3], but further analysis of the HYVET study showed
that both frail and fitter patients appeared to gain from
antihypertensive treatment [5].
In 2012 the Dutch cardiovascular risk management
guidelines [7] set systolic blood pressure (SBP) target
values below 150–160 mmHg in older patients. Simi-
larly, guidelines of the British National Institute for
Health and Care Excellence (NICE), the European
Society of Hypertension (ESH) and the European Society
of Cardiology (ESC) recommended SBP target values
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below 150 mmHg in patients over 80 years old [8, 9].
However, there is evidence that compliance to these re-
vised guidelines is incomplete [10], particularly in older
patients [11, 12] and a recent review suggested that in-
deed, each patient’s individual clinical condition may
need to be taken into account for optimal HT treatment
[13]. In practice, other than patient-related barriers, e.g.
doctor or system related barriers, whether they are ap-
propriate or inappropriate, may play a role in incomplete
guideline compliance.
In light of the conflicting evidence and lack of infor-
mation whether GPs manage HT differently in older pa-
tients, we wanted to investigate how HT is diagnosed




We conducted a retrospective cohort study within the
Integrated Primary Care Information database (IPCI); a
longitudinal observational dynamic database which con-
tains the complete electronic medical records of the pa-
tients of 159 GP’s surgeries in the Netherlands during
the full study period. In the Dutch health care system,
patients are registered with a single GP who acts as a
gatekeeper for and receiver of information from second-
ary care. Details of the database have been published
elsewhere. [14, 15]. In brief, the database contains an-
onymous longitudinal data on demographics, symptoms
and diagnoses (in coded and free text format), referrals,
laboratory findings, discharge letters, and drug prescrip-
tions. To maximize completeness of the data, GPs
participating in the IPCI project are not allowed to
maintain a system of paper-based records besides the
electronic medical records. To enhance data quality,
GPs are encouraged to encode their assessments,
which is also facilitated by their record systems. The
IPCI database system complies with European Union
guidelines on the use of data for medical research
and has been proven valid for pharmaco-epidemiological
studies [15].
Study population and study cohort
Within the IPCI database we defined the study popula-
tion as all patients who were present in the database
during the entire period of the 1st of September 2009 to
the 31st of December 2012.
Within this study population, we defined a cohort
in which we included all patients aged 60 years or
older, with at least one BP measurement between1st
of September 2010 and August 31th 2012 (the inclu-
sion period). The date of inclusion was defined as the
date of the first BP measurement within the inclusion
period. Follow-up for this cohort started upon first
BP measurement until maximum four months after
inclusion. We excluded patients who, prior to their
first BP measurement, had already been diagnosed
with HT, diabetes mellitus or atherosclerotic cardiovascu-
lar disease, including atrial fibrillation. We furthermore
excluded patients who had received antihypertensive
medication in the 12 months preceding the first BP meas-
urement. In Appendix 1, we provide a more detailed over-
view of these criteria.
Covariates
Age at date of inclusion was considered and stratified in
3 categories namely 60–69, 70–79 and 80+ years old.
SBP was retrieved from the patient’s measurement file and
categorised into 5 strata namely lower than 140 mmHg,
140–159 mmHg, 160–179 mmHg, 180–199 mmHg and
higher than 200 mmHg.
Outcome parameters
The two outcomes of interest were: diagnosis of HT and
start of anti-hypertensive treatment. Diagnosis of HT
was based on disease codes and the complete medical
record was searched for International Classification of
Primary Care (ICPC) codes of HT: K86 (essential HT
without organic damage), within one month after the
first BP measurement (ie inclusion). Treatment for HT
was based on prescriptions of antihypertensive drugs
(thiazide diuretics, calcium channel blockers, renin-
angiotensin-aldosterone system (RAAS) inhibitors and
beta blockers) within 4 months after the first BP meas-
urement that preceded the HT diagnosis. Details about
the relevant Anatomical Therapeutic Chemical (ATC)
codes are described in Appendix 2.
Analysis
Proportions (with Wilson 95%CI) of patients with a new
diagnosis and treatment of HT were calculated stratified
by age group and SBP category. Within each SBP
category the age-outcome relation was tested using
linear-by-linear association.
SBP Z-scores were calculated using sex and age specific
reference values from the World Health Organization
(WHO) [16]. For example: for a 65-year-old woman the
reference mean SBP is 151 mmHg, with a standard devi-
ation of 23. If her SBP is 151 mmHg the SBP Z-score
would be 0 and if her SBP is 174 mmHg, her SBP Z-score
would be (174–151)/23 = 1.
The possible influence of these SBP Z-scores, age and
gender on the probability of HT diagnosis was tested
using logistic regression. If SBP Z-score and age or gen-
der had a significant contribution to the model, the sig-
nificance of their interaction was tested.
In patients with an HT diagnosis, influences on the
probability to get treatment were tested similarly.
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Results
Patient characteristics
Our cohort consisted of 19,500 patients aged 60+ with
at least one BP measurement and without a diagnosis of
HT, DM or arterial cardiovascular disease or antihyper-
tensive medication prior to the first BP measurement.
The source population comprised of 131,545 patients
aged 60 years or older.
Sixty one percent were 60–69 years old, 28.2 % were
70–79 years old and 10.8 % were 80 years or older. The
percentages of women in these age groups were 55.7,
57.9 and 64.0 % respectively. Table 1 shows SBP values,
by age group and gender.
Outcomes
Percentages of patients with diagnosis of hypertension,
by age and systolic blood pressure
Figure 1 shows the percentages of patients with a new
diagnosis of HT for each age- and SBP-group with 95 %
confidence intervals. The corresponding numbers are
reported in Table 2.
Of those patients with a BP between 160 and
179 mmHg and aged 60–69 years, 18.2 % (16.5–20.0)
had a new diagnosis of HT within 1 month. For patients
of 70–79 years and 80 years and older within the same
BP group these percentages were 12.1 % (10.2–14.2) and
7.1 % (5.0–9.9) respectively.
The p-value for trends between age groups was signifi-
cant in all three BP groups between 140 and 200 mmHg,
indicating that, within these SBP groups, older patients
are less likely to be diagnosed as hypertensive than
younger patients.
Effect of systolic blood pressure Z-scores, age and gender
on new diagnosis of hypertension
The outcomes of the logistic regression analysis with
newly diagnosed HT as outcome were as follows. The
unadjusted odds ratio (OR) for the SBP Z-score was
4.30 (95 % CI 4.01 – 4.61; p < 0.001). Adjusted for
age, the OR for the SBP Z-score was 4.35 (4.05–4.67;
p < 0.001).
This adjusted OR of 4.35 for SBP Z-score means that
the odds of new diagnosis of HT is multiplied by 4.35
when the SBP increases by one standard deviation. Ad-
justed for SBP Z-score, age had a significant effect on
the probability of diagnosis of HT (OR 0.98 per year age
increase, 95 % CI 0.97–0.99, p > 0.001).
We found no significant interaction between age and
SBP Z-score in our model. Gender had no significant
contribution to the model.
Table 1 Systolic Blood Pressure by gender and age; mean SBP with standard deviation; percentages above 140 mmHg and
160 mmHg
Age N Gender SBP (mmHg) SBP > 140 mmHg SBP > 160 mmHg
Mean SD
60–69 5270 male 142 19.9 55.8 % 20.7 %
6619 female 141 20.7 53.8 % 20.8 %
70–79 2316 male 145 20.8 63.1 % 26.4 %
3182 female 146 21.2 65.1 % 28.3 %
80 + 761 male 146 21.6 64.5 % 27.9 %
1352 female 149 22.2 71.1 % 32.0 %
Fig. 1 Observed proportions with hypertension diagnosis, by systolic blood pressure and age, with Wilson 95 % confidence intervals
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This model permits calculating the probability of a
new diagnosis of HT on basis of a given SBP Z value
and age. For example: a 60-year-old male patient with a
SBP Z-score +1 (165 mmHg) has a predicted probability
of a new diagnosis of 15.9 % (95 % CI: 14.5–17.3 %). The
probability for an 80-year-old with the same SBP Z-score
(170 mmHg), is only 11.2 % (95 % CI: 10.1–12.5 %).
These findings are illustrated in Fig. 2 which shows
the predicted probabilities of a new HT diagnosis, in
relation to SBP and age.
Percentages of patients with treatment of hypertension,
by age and systolic blood pressure
We calculated the percentages of patients that received
antihypertensive treatment within 4 months after being
diagnosed as having HT. In the group with an SBP of
140–159 mmHg for instance, 45.3 % (37.2–53.6) of the
60–69 years old patients and 50.0 % (18.8–81.8) of the
80 years and older patients were treated; and in the
group with an SBP of 160–179 mmHg, 69.9 % (64.7–
74.6) of the 60–69 years old patients and 50.0 % (33.2–
66.8) of the 80 years and older patients were treated. For
details on all age groups please see Table 3. None of the
p-values for age-related trends were significant.
Effect of systolic blood pressure Z-scores, age and gender
on treatment after diagnosis of hypertension
For the outcome treatment, the OR for the SBP Z-score
was 2.96 (95 % CI: 2.45–3.57).
Age and gender had no significant contribution to the
model. (OR for age 1.00, 95 % CI: 0.98–1.02, p = 0.82).
Discussion
Strengths and limitations
The study included a large and, because we excluded pa-
tients with diabetes, existing HT and other cardiovascu-
lar conditions, homogenous cohort. Moreover, the data
were collected during the normal practice of GPs, and
reflect how they manage HT in daily care. We have no
reason to assume that GPs participating in IPCI differ in
their HT management from their non-participating col-
leagues; therefore, the conclusions may be generalized to
the Dutch population.
In the study we only studied recorded BP measure-
ments and diagnoses. Especially diagnoses by medical
specialists may not all be recorded by the GP. Therefore,
registration bias is possible. All patients in our study
have an immortal time of two years, which may intro-
duce age related bias, as older patients have a shorter life
expectancy and hence are less likely to be included in
the cohort. Moreover, in general, diagnosis of HT is
based on more than one measurement, which is not
accounted for in our study. This may further explain
why the percentages with a diagnosis of HT are rather
Table 2 New diagnosis of hypertension within one month after
inclusion
SBP (mmHg) Age (years) n New Diagnosis (%) p for trend
<= 130 60–69 5385 0.5 (0.3–0.7) 0.61
70–79 1965 0.6 (0.3–1.1)
80+ 661 0.2 (0.0–0.9)
140–159 60–69 4029 3.4 (2.9–4.0) <0.001
70–79 2019 2.5 (1.9–.3.2)
80+ 807 0.7 (0.3–1.6)
160–179 60–69 1829 18.2 (16.5–20.0) <0.001
70–79 1028 12.1 (10.2–14.2)
80+ 424 7.1 (5.0–9.9)
180–199 60–69 504 34.9 (30.9–39.2) 0.002
70–79 392 30.9 (26.5–35.6)
80+ 156 21.2 (15.5–28.2)
200+ 60–69 142 48.6 (40.5–56.7) 0.24
70–79 94 39.4 (30.1–49.5)
80+ 65 41.5 (30.4–53.7)
Percentage with Wilson 95 % CI by age group and blood pressure group;
p-values for linear by linear association between age groups
Fig. 2 Predicted probability of hypertension diagnosis, by systolic blood pressure Z-score and age; based on logistic regression analysis
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low. A further limitation may be that this study does not
permit any insight into the reason why older patients are
less likely to be diagnosed as having HT.
For our study we excluded patients with co-
morbidities such as DM and pre-existing cardiovascular
disease. On the one hand this reduces the generalizability
of the results. On the other hand, excluding patients with
these co-morbidities eliminates these co-morbidities as
potential confounders because, according to international
guidelines, these patients should have strict BP control. By
excluding these patients, it was easier to study the impact
of age and BP on the outcomes. A strength of this study is
that, by using reference SBP values we could control for
the natural increase of BP by age. As reference BP data for
the older Dutch population were are not readily available,
we used data from the North-western Europe population,
which may be a limitation. In our cohort, mean BPs in all
age strata were slightly lower than the used reference
values [16]. This may be explained by the fact that we ex-
cluded patients already diagnosed with HT.
Comparison with existing literature
Although previous studies compared HT management
in older to younger age groups [11, 12], to our know-
ledge, this is the first study to take age-specific SBP
levels into account.
The proportions of patients with a new diagnosis of HT
were rather low and this seems in accordance with exist-
ing literature about guideline adherence [10]. However,
our follow up period of one month does not allow conclu-
sions about guideline adherence as some patients may re-
ceive the diagnosis of HT later on.
Although we demonstrate that older patients are less
likely to receive a diagnosis of HT, our data do not pro-
vide any insight why these patients are less likely to be
diagnosed. A possible explanation may be the clinical
condition, especially frailty in older patients as an im-
portant reason to refrain from treatment of HT [3, 9].
Other barriers to guideline compliance in older people
are outside the scope of this study.
Conclusions
This study showed that GPs are less inclined to diagnose
HT with increasing age, but do not withhold treatment
when they diagnose HT in older patients.
Increasing life expectancy will lead to larger numbers
of older patients, yet the optimal management of HT in
this age group has not been elucidated. In this respect
there are indications that BP target values will depend
on features, such as frailty, in older patients.
More research, especially in the form of trials, will be
needed to determine whether the Dutch GP’s reserva-
tions to diagnose HT in older patients are correct.
Appendix 1
Inclusion criteria based on the presence of ICPC
codes. Diagnosis of HT was based on the presence of
the ICPC code: K86 ‘hypertension without organic
damage’. Diagnosis of atherosclerotic cardiovascular
disease was based on the presence of the following
ICPC codes:K87 'hypertension with organic damage',
K74 'angina pectoris', K75 'acute myocardial infarc-
tion', K76 'other chronic cardiovascular disease', K77
'cardiac failure', K78 'atrial fibrillation', K89 'transient
ischemic attack', K90 cerebrovascular disease, K9l
'atherosclerosis', K92.01 'intermittent claudication',
and K99.01 'aortic aneurysm'.
Appendix 2
Classification criteria for antihypertensive medication,
based on ATC codes. The Anatomical Therapeutic
Chemical (ATC) Classification System divides medica-
tion into groups, according to organ system and mode
of action. Prescriptions of antihypertensive medication
within the follow up period was based on the presence
of one or more of the following ATC codes:
1. low ceiling diuretics (ATC C03A, C03B, C03E,
C07B, C07D, C09BA and C09DA)
2. beta blockers (C07)
3. RAAS inhibitors (C09)
4. calcium channel blockers with mainly vascular
effects (C08C, C09BB, C09BB)
Table 3 Treatment within four months after inclusion in
diagnosed hypertension patients
SBP (mmHg) Age (years) N Antihypertensive
treatment (%)
p for trend
<=139 60–69 26 30.8 (16.5–50.0) 0.70
70–79 12 33.3 (13.8–60.9)
80+ 1 0.0 (0.0–79.3)
140–159 60–69 137 45.3 (37.2–53.6) 0.70
70–79 50 48.0 (44.8–62.5)
80+ 6 50.0 (18.8–81.8)
160–179 60–69 332 69.9 (64.7–74.6) 0.15
70–79 124 71.0 (62.4–78.2)
80+ 30 50.0 (33.2–66.8)
180–199 60–69 176 86.9 (81.2–91.1) 0.25
70–79 121 81.8 (74.0–87.7)
80+ 33 81.8 (65.6–91.4)
200+ 60–69 69 95.7 (88.0–98.5) 0.28
70–79 37 97.3 (86.2–99.5)
80+ 27 88.9 (71.9–96.1)
Percentage with Wilson 95 % CI by age group and blood pressure group;
p-values for linear by linear association between age groups
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